CRM197 and tetanus toxoid carrier protein-specific B-cell and T-cell receptors (CRM197/TT-specific BCRs and TCRs)

CRM197 and tetanus toxoid (TT) carrier protein-specific B-cell and T-cell receptors are the primary immunological targets for conjugate vaccines designed to prevent bacterial infections. CRM197 is a non-toxic mutant of diphtheria toxin, while TT is a detoxified form of the tetanus toxin; both serve as highly immunogenic scaffolds for poorly immunogenic polysaccharides (Source: Shinefield, Vaccine, 2010). When a conjugate vaccine is administered, B-cell receptors (BCRs) recognize the polysaccharide or carrier epitopes, leading to the internalization and processing of the carrier protein. Subsequently, carrier-derived peptides are presented on MHC class II molecules to T-cell receptors (TCRs) on CD4+ helper T-cells (Source: Avci et al., Nature Medicine, 2011). This interaction triggers T-cell activation and the provision of essential signals to B-cells, facilitating class switching and the development of long-lasting immunological memory (Source: Pichichero, Human Vaccines & Immunotherapeutics, 2013). These receptors are critical for converting T-independent polysaccharide antigens into T-dependent antigens, which is essential for efficacy in infants. By targeting these specific receptors, conjugate vaccines like Prevnar and ActHIB have significantly reduced the global burden of pneumonia and meningitis (Source: CDC, Pink Book). Understanding the interaction between these receptors and carrier proteins is also crucial for managing potential safety concerns like carrier-induced epitopic suppression (Source: Schutze et al., Journal of Immunology, 1985).

Other names

Carrier protein-specific lymphocyte receptorsCRM197-specific receptorsTetanus toxoid-specific receptorsConjugate vaccine carrier receptorsCarrier-specific B-cell and T-cell receptors

Conjugate vaccines utilize these receptors to convert T-cell independent antigens into T-cell dependent ones. B-cell receptors (BCRs) bind the conjugate, leading to endocytic internalization and proteolytic processing of the carrier protein (CRM197 or TT). The resulting peptides are loaded onto MHC class II molecules and presented to carrier-specific T-cell receptors (TCRs) on CD4+ T-cells. This TCR-MHC II interaction, along with co-stimulatory signals, induces T-cell help, which promotes B-cell proliferation, isotype switching from IgM to IgG, and the formation of memory B-cells (Source: Pollard et al., Nature Reviews Immunology, 2009; Avci et al., Nature Medicine, 2011).